ABSTRACT

Among the various routes of administration, the oral route remains the most convenient and commonly employed route for drug delivery. The oral conventional drug delivery systems have some drawbacks, such as possibility of gastrointestinal destruction of labile molecules, low absorption of macromolecules, slow onset of action, and unavoidable fluctuation in the concentration of drugs which can either lead to under-or over medication with concomitant adverse effects, especially for drugs with small therapeutic index. Therefore, it became essential to design novel oral drug delivery systems to achieve quick dissolution, absorption, rapid onset of action and reduction of drug dose. Among those novel drug delivery systems are oral disintegrating tablets (ODTs). The purpose of this review article is to report the recent advances in ODT systems with emphasis on their preparations, characterizations and applications. Also, it highlights future prospects and possible challenges in the development of an ideal ODT system.

Keywords: Oral disintegrating tablets, Preparations, Characterizations, Applications, Future prospects, Challenges

INTRODUCTION

The oral mucosal cavity is a very attractive and feasible site for local and systemic drug delivery, since the mucosal membranes, upon which drug delivery systems are placed, are readily accessible by the patients [1]. The oral mucosal drug delivery exhibits many advantages over other routes of drug administration, which include increased accessibility by the patients as the dosage form can be accurately placed on the desired oral cavity membrane location and can be easily removed in order to terminate delivery if signs of adverse reactions are observed during treatment which increases patient acceptance [1-3]. Moreover, the oral mucosa is a well-vascularised tissue directly draining into the jugular vein [4], hence, allowing direct delivery into the systemic circulation and avoidance of first-pass hepatic degradation. Oral mucosal delivery also avoids the gastrointestinal tract (GIT) environment preventing possible drug hydrolysis in the GIT, in addition to avoiding enzymatic barriers; i.e. low gastric pH and protease enzymes. However, the oral mucosal drug delivery represents a challenging area because of the inherent functions of the oral cavity as swallowing, chewing and speaking [5]. Furthermore, saliva is constantly secreted into the buccal cavity from both major and minor salivary glands, causing severe dilution of the drug or excessively fast erosion of dosage forms. Furthermore, salivation leads to swallowing which removes the drug from the targeted site of absorption. Moreover, the oral mucosa has a smaller absorptive surface area which is approximately 214 cm² [6] compared to the gastrointestinal mucosa (350,000 cm²). Despite the aforementioned limitations, oral mucosal delivery remains a viable option for drug delivery [3].

There are two major routes of drug absorption via oral mucosa; the transcellular (where drugs permeate directly through the cells) and paracellular (where drugs permeate by passive diffusion through the spaces between the cells) routes. The drug absorption process by passive diffusion is best expressed by Fick’s first law [7], which states that drug molecules diffuse from a region of higher to lower concentration until equilibrium is achieved.

\[
p = \frac{D_{xy}}{h} \quad \text{(Eq. 1)}
\]

\[
A = \frac{P}{C.S.t} = \frac{D_{xy}}{h} \times C.S.t \quad \text{(Eq. 2)}
\]

where \(P\) is the permeability coefficient, \(A\) is the amount of drug absorbed via oral mucosa, \(D\) is the diffusion coefficient of the drug, \(K_d\) is the partition coefficient of the drug in between the oral mucosa and the specific medium used to deliver the drug, \(h\) is the thickness of the oral mucosa, \(C\) is the free drug concentration in the medium used to deliver the drug, \(S\) is the surface area of the oral mucosa, and \(t\) is the duration or time of drug interacting the oral mucosa.

There must be a balance between partition coefficient and drug's solubility for a suitable oral mucosal delivery. In general, the permeability coefficient of lipophilic drugs is high, low for hydrophilic drugs, and vice versa for solubility (i.e. the aqueous solubility of lipophilic drugs are usually lower than the hydrophilic drugs). Thus, the amount of drug absorbed via oral mucosa may be low for high lipophilic drugs. As a result, permeation enhancers are subsequently used to enhance drug absorption and permeation [7].

Understanding the physicochemical and solid-state properties of a drug substance is essential to obtain a rational formulation process. The desirable physicochemical and solid-state properties for drug delivery through oral mucosa are shown in table 1 [3]. Two factors mainly affect the effectiveness of oral drug delivery systems; the retention time of the drug delivery system in contact with the oral mucosa and its permeation rate.

The need for development of oral disintegrating tablets

Conventional oral dosage forms like tablets and capsules pose a great swallowing problem for paediatrics and geriatrics. Approximately 35% of the general population suffers from dysphasia [8]. Oral disintegrating tablets (ODTs) are tablets which are placed in the mouth and then get dispersed in saliva without the need of water [9-11]. ODTs are considered the dosage form of choice for psychiatric patients, patients requiring fast intervention as well as patients suffering from nausea, vomiting and motion sickness [12], since the ODT system presents a patient friendly dosage form which ensures patient compliance and adherence to treatment.

ODTs combine the advantages of solid and liquid dosage forms. Like conventional tablets, ODTs present accurate drug dosing, ease of both manufacturing and packaging, good chemical stability, as well as ease of handling by patients [13]. They also exhibit the smooth mouth feel and avoidance of swallowing problems encountered with
Various pharmaceutical techniques are used in the manufacture of ODTs, including: (1) freeze-drying or lyophilization [34], (2) spray-drying [35, 36], (3) molding [37, 38], (4) phase transition process [39], (5) melt-granulation [40-42], (6) sublimation [43, 44] (7) mass extrusion [45], (8) cotton candy process [46, 47], (9) nanonization [48], and (10) direct compression [40, 49-53]. Admittedly, direct compression is the most commonly used technique in the manufacture of ODTs, owing to its easy-implementation and cost-effectiveness.

Table 1: The desirable physicochemical and solid-state properties of a drug delivery through oral mucosa [3]

| Property                      | Normal range                      |
|-------------------------------|-----------------------------------|
| Aqueous solubility            | >1 mg/ml                          |
| Lipophilicity                 | 10-oil: water partition coefficient<1000 |
| Molecular weight              | <500 Da                           |
| Melting point                 | <200 °C                           |
| pH of saturated aqueous solution | pH 5–9                            |
| Required dose deliverable     | <10 mg/day                         |
| Irritation potential          | No irritation to buccal tissue     |

Table 2: Choice of drug candidates for oral disintegrating tablets [15]

| Suitable drug candidates for ODTs                         | Unsuitable drug candidates for ODTs                        |
|-----------------------------------------------------------|-----------------------------------------------------------|
| No bitter taste                                           | Short half-life and frequent dosing                        |
| Good stability in water and saliva                       | Drug having very bitter taste                              |
| Taken in small doses                                      | Required controlled or sustained release                   |

The new generation of oral disintegrating tablets

Table 2: Choice of drug candidates for oral disintegrating tablets [15]

| Suitable drug candidates for ODTs                         | Unsuitable drug candidates for ODTs                        |
|-----------------------------------------------------------|-----------------------------------------------------------|
| No bitter taste                                           | Short half-life and frequent dosing                        |
| Good stability in water and saliva                       | Drug having very bitter taste                              |
| Taken in small doses                                      | Required controlled or sustained release                   |

| Property                      | Normal range                      |
|-------------------------------|-----------------------------------|
| Aqueous solubility            | >1 mg/ml                          |
| Lipophilicity                 | 10-oil: water partition coefficient<1000 |
| Molecular weight              | <500 Da                           |
| Melting point                 | <200 °C                           |
| pH of saturated aqueous solution | pH 5–9                            |
| Required dose deliverable     | <10 mg/day                         |
| Irritation potential          | No irritation to buccal tissue     |

| Property                      | Normal range                      |
|-------------------------------|-----------------------------------|
| Aqueous solubility            | >1 mg/ml                          |
| Lipophilicity                 | 10-oil: water partition coefficient<1000 |
| Molecular weight              | <500 Da                           |
| Melting point                 | <200 °C                           |
| pH of saturated aqueous solution | pH 5–9                            |
| Required dose deliverable     | <10 mg/day                         |
| Irritation potential          | No irritation to buccal tissue     |

The first generation ODTs suffered from many undesirable traits, mainly low density, poor mechanical strength, brittleness and difficulty in handling. This necessitated blister packaging, which is not patient friendly, and causes increase in production expenses [16]. Another disadvantage of first generation ODTs was the difficulty of masking the taste of bitter active ingredients loaded within these tablets [17], which led to the emergence of new generation ODTs that overcame the problems of taste masking, allowed for modified release of medications, solved solubility and bioavailability problems, resulted in ODT tablets with excellent physical and mechanical robustness, mouth feel sensation, disintegration and dissolution properties.

Challenges in formulating and developing oral disintegrating tablets

There are several challenges in formulating and developing ODTs, such as: (1) palatability and acceptability [18], (2) mechanical strength [19], (3) the amount of drug that can be incorporated into an ODT system [19], (4) size of tablet [20], (5) hygroscopicity and physical and chemical stability. Taste-masking of bitter and unpleasant taste of drugs is essential in order to achieve patient acceptability and compliance. Different techniques were developed and introduced for bitterness masking [24-32]. One of the most commonly used techniques for taste-masking of bitter and unpleasant APIs or drugs is the coacervation process [33]. Coacervation process has successfully taste-masked a wide variety of bitter drugs, including but not limited to, aceterminophen, cetirizine, ibuprofen, pseudoephedrine, ranitidine, sumatriptan, theophylline and zolpidem [33]. Coupling controlled release behaviour with specialized functional polymers and efficient coating processes creates ODT systems with modified and sustained release profiles.

Formulation processes for developing oral disintegrating tablets

Various pharmaceutical techniques are used in the manufacture of ODTs, including: (1) freeze-drying or lyophilization [34], (2) spray-drying [35, 36], (3) molding [37, 38], (4) phase transition process [39], (5) melt-granulation [40-42], (6) sublimation [43, 44] (7) mass extrusion [45], (8) cotton candy process [46, 47], (9) nanonization [48], and (10) direct compression [40, 49-53]. Admittedly, direct compression is the most commonly used technique in the manufacture of ODTs, owing to its easy-implementation and cost-effectiveness [40, 53]. These techniques are described below in detail.

Freeze-drying or lyophilization technique

Freeze-drying, also known as lyophilization or cryodesiccation, is a technique that yields amorphous highly porous structures with rapid disintegration and dissolution. Ondispersible tablets made by lyophilization are prepared by dissolving the drug substance in an aqueous mixture of carrier/polymer, the solution is then poured into the holes of blister packs which are subsequently frozen in order to continue the freeze-drying cycle, followed by blistering and finally packaging. Lyophilization technique is very suitable for heat-sensitive drugs (i.e. thermo-labile substances). Although ODTs prepared by freeze-drying process showed rapid disintegration and dissolution properties, but their industrial applications are limited since it is a high cost technique particularly in equipment and packing materials [34].

Spray-drying technique

Spray-drying is widely used in pharmaceutical industries nowadays. It provides a fast, efficient and economical way of removing solvents and producing free flowing, highly porous particles. In this process, gelatin is commonly used as a supporting agent, mannitol as a bulking agent, and sodium starch glycinate, crosscarmellose sodium and/or crospovidone as superdisintegrants. Ondispersible tablets made by spray-drying have been reported to disintegrate and dissolve in less than 20 seconds [35, 36].

Interestingly, Allen and Wang [54] fabricated a particulate support matrix for preparing ODTs by spray-drying, consisting of supporting agents of two polypeptide components from gelatin, a bulking agent (mannitol) and a volatilizing agent (ethyl alcohol). In order to maintain the net charges of both polypeptide components, a buffer system of an acidifying agent (citric acid) and an alkalizing agent (sodium bicarbonate) is prepared and added to the tablet mixture. The mixture of the aforementioned components is then spray-dried to obtain porous granules. By incorporating a volatilizing agent as ethyl alcohol, the surface tension of the droplets is further reduced, and more porous structures are created. An effervescent agent could be optionally added to further enhance the dissolution.

Molding method

Molding is a solid dispersion method, involving the dispersion of APIs in an inert water-soluble carrier or matrix at solid-state form, prepared by solvent or heat method. Solvent method involves moistening the powder mixture with alcoholic or hydroalcoholic solvent, then molding into tablets under reduced pressure to form wet paste. This process is known as compression molding. The solvent is
then removed from the wet paste by air-drying. The resulting tablets possess fine powders and highly porous structures. Solid dispersions are prepared directly from a molten matrix in which the drug is dispersed in or by vaporizing the solvent at ambient pressure (no vacuum lyophilization). The drug molecule can be in the form of discrete-particles or microparticles, completely or partially dispersed in the molten matrix. Because of their composition, molded tablets offer rapid disintegration, dissolution and improved taste, but they suffer the disadvantage of poor mechanical strength. Compared to freeze-drying, molded tablets are simpler in production and easier for industrial scale-up, although disintegration times may not be comparable to those of lyophilized forms [37, 38].

Phase transition process
This process involves a combination of low and high melting point sugar alcohols. Optimizing the phase transition in the manufacturing process is important for formulating tablets without the need of any equipment. Kuno et al. [39] prepared ODTs by phase transition process using compressible powder mixture of erythritol (a sugar alcohol with melting point: 122 °C) and xylitol (a sugar alcohol with melting point: 93-95 °C), followed by heating at 93 °C for a period of 15 min. As a result of heating, the median pore size of tablets increased, as well as tablet hardness.

Melt-granulation technique
The melt-granulation technique is based on incorporating a hydrophilic melting binder in the formulation, which increases the physical resistance of tablets and helps their disintegration and dissolution. In comparison with other granulation techniques as dry- and wet-granulation, melt-granulation is advantageous as no aqueous, alcoholic or even organic solvents are required. Melt-granulation is less time-consuming, cost-effective and easy to perform [40-42].

Interestingly, Abdelbary et al. [41] described a new approach for the preparation of ODTs of high mechanical strength involving the use of a hydrophilic waxy binder, PEG-6-stearate, commercially known as Superpolystate® by melt-granulation. Moreover, Agiba et al. [40] developed high-dose nutraceutical ODTs of glucosamine sulphate and chondroitin sulphate using a blend of hydrophilic melting binders as high molecular weight polyethylene glycols (PEG-4000 and PEG-6000). Although ODTs weighed around 1.30 gm with 60% drug load, they showed quick disintegration and dissolution properties, as well as a high mechanical strength.

Sublimation method
In this method, a sublimating agent like camphor is removed from the compressed tablets by sublimation. Highly porous structures are created as a result of removing camphor from the compressed tablets. The resulted tablets, characterized by high porous structures, could achieve fast disintegration in saliva. Examples of other volatile materials are adipic acid, ammonium carbonate, ammonium bicarbonate, arachidic acid, capric acid, camphor, menthol, myristic acid, and palmitic acid, thymol and urea. The sublimation temperature range is from 40 to 60 °C [43, 44].

Interestingly, Heinemann [55] prepared a highly porous tablet structure by using a mixture of volatile adipic acid, which was removed at the end by heating. On the other hand, Roser and Blair [56] removed the volatile materials by using vacuum, which reduced the dissolution-time from 15 min for the tablets containing trehalose (a disaccharide composed of 2 glucose units) alone to less than 1 minute. Moreover, Lo [57] developed an efficient method for the preparation of fast-dissolving tablets with highly porous structures.

Mass extrusion technique
In mass extrusion, the active and inactive ingredients are first softened using PEGs mixture and methanol as organic solvent, followed by extrusion and division into tablets using heated blades [45].

Cotton candy process
This technique involves the formation of a matrix of poly- or monosaccharides using flash melting and spinning to form floss like crystalline structure, which is then mixed with active/inactive ingredients and compressed into ODTs. This process can easily accommodate large doses of APIs with an improved mechanical strength. However, high-process temperature limits its use [46, 47].

Nanomization
Nanomelt is a recently developed nano-based drug delivery system, involving a reduction of drug particle size to be in nano-scale range by using a proprietary wet-milling technique. APIs usually present in the form of nanoparticles or nanocrystals are stabilized against possible agglomeration by surface adsorption onto preselected stabilizing agents incorporated into ODT systems. This technique is suitable for poorly water-soluble drugs, and the produced tablets exhibit rapid disintegration and dissolution [48].

Direct compression
Direct compression is the simplest, easiest and most widely used technique in ODT manufacturing, owing to its easy-implementation and cost-effectiveness. It involves using a blend of ingredients, which can provide rapid disintegration, as well as high physical integrity and stability. Sugar-based excipients as mannitol, sorbitol and lactose are commonly used as bulking agents, because of their high aqueous solubility and good taste-masking properties [40, 49-53].

In general, any tablet dosage form contains one or more of diluents/fillers, binders/adhesives, disintegrants, superdisintegrants, glidants/flowing agent and lubricant. Disintegrants and superdisintegrants are mainly incorporated into tablet formulations to promote their disintegration and dissolution. As the ability of the tablet to rapidly disintegrate is a prerequisite in ODT systems, ODTs usually contain high concentrations of disintegrants and superdisintegrants. Examples of disintegrants and superdisintegrants are listed below.

Disintegrants and superdisintegrants
Various disintegrants and superdisintegrants are available in the pharmaceutical market and are readily used for the manufacture of ODTs.

Starch and modified starch
Starch is a versatile excipient with many applications in oral solid dosage forms as a diluent, binder, and disintegrant. Starch acts as a disintegrant at a concentration of 2-25% (w/w), with an optimum concentration of 15% (w/w) [58-61]. However, before using starch as a disintegrant at a concentration of 3-25% (w/w), it is necessary taking into consideration that concentrations greater than 0.25% (w/w) may have adverse effects on tablet disintegration and dissolution. As the ability of the tablet to rapidly disintegrate is a prerequisite in ODT systems, ODTs usually contain high concentrations of disintegrants and superdisintegrants. Examples of disintegrants and superdisintegrants are listed below.

Agiba et al. Int J Pharm Pharm Sci, Vol 11, Issue 9, 8-20
Cellulose and modified cellulose

Microcrystalline cellulose, commercially known as Avicel PH, is widely used in oral solid dosage forms as a binder or diluent in both direct-compression, dry- and wet-granulation methods, with some lubricant and disintegrant properties [58].

Croskemellose sodium or cross-linked carboxymethylcellulose sodium, commercially known as Ac-Di-So®, Exciplex® or Primellose® is widely used in oral solid dosage forms as a tablet superdisintegrant in both direct compression, dry- and wet-granulations [58]. In wet-granulation, it can be added intra- and extragranularly, so that the wicking and swelling ability of the superdisintegrant is optimized [70, 71].

Low-substituted hydroxypropyl cellulose (L-HPC) is primarily used as a disintegrant in both dry- and wet-granulations, also used in the preparation of ODTs prepared by direct compression [58]. There are different grades of L-HPC that have different substitution levels and particle sizes. For example, LH-11 has the longest fibrous particles, and is typically used as a disintegrant for tablets prepared by direct compression method, while LH-21 is less fibrous and used in case of tablets prepared by wet-granulation method. LH-31 is a small particle size grade and mainly used in extrusion process to produce granules. LH-81 is non-fibrous, high-density grade, typically produced for fluid-bed granulation. Low substitution grades LH-22 and LH-32 are usually used for enhancing the disintegration, and their concentrations are mainly depending on the characteristics of APIs [72]. The typical concentration of L-HPC in a solid formulation ranges from 5–50% (w/w) [58].

Crosnovidone [58]

Crosnovidone or cross-linked povidone (commercially known Kollidon CL-M®; Polysplasdone XL®) is a tablet superdisintegrant used at a concentration of 2–5% (w/w) in tablets prepared by direct compression, dry- or wet-granulations [73]. Crosnovidone can also be used as a solubility enhancer for increasing the solubility and dissolution of poorly absorbed drugs by coevaporation technique.

Resin and its derivatives

Ion exchange resins have been introduced as tablet disintegrants. The most commonly used ion exchange resin is polacrilin potassium. Polacrilin potassium is a highly hydrophilic cation exchange resin having good swelling properties [74] as well as wicking and strain recovery characteristics [75, 76]. It is usually used in a concentration of 2-10% (w/w) in tablet formulations, although 2% (w/w) was reported to be sufficient.

Mechanisms of disintegrants

Swelling

The most common mechanism of tablet disintegration is swelling. Swelling is basically a dimension-elongation process in which particles enlarge in every direction to push apart tablet components, thereby initiating the process of breaking-up of the tablet matrix [77, 78]. The swelling property of a disintegrant depends on many factors including chemical structure and degree of crosslinking [79]. Porosity of the tablet compact plays also a significant role in determining the performance rate of swelling disintegrants. A tablet matrix with low porosity and void spaces would reduce liquid penetration and thereby delay or prolong the disintegration time, and vice versa [77]. Therefore, tablets should be prepared at an optimal porosity to provide adequate mechanical integrity and good disintegrability [80]. There is a positive correlation between the disintegration force development rate and the disintegration time, while there is no correlation between the extent of swelling of a disintegrant and the maximum disintegration force. Thus, the disintegration force development rate is essential for rapid tablet matrix disintegration [80].

Wicking (capillary action)

Wicking is a process of liquid penetration by capillary action into the microstructured spaces in the tablet compact to displace the entrapped air (i.e. through porous structures within the tablet compact) [77, 81, 82]. As other water-soluble ingredients rather than disintegrants can contribute to improving disintegration by increasing tablet porosity as high-molecular weight polyethylene glycols, so wicking cannot be classified as a primary disintegration mechanism. However, water penetration into the tablet compact is essential for disintegrant activation [79]. Thus, the penetration rate will mainly depend on the balance between capillary and opposite viscous forces [83].

Strain recovery (process of deformation)

In tabletting process, tablet components are subjected to a high compaction pressure. During compaction, particles deform and interparticulate bonds are disturbed. Strain recovery is a reversible viscoelastic deformation process [84]. It elucidates the process of mechanical activation of disintegrant polymer chains when getting into contact with the aqueous media, causing a partial recovery into their original shapes [77]. Moreover, disintegration media contributes to the plasticization of disintegrant polymer chains and assists their accommodation into the most energetically stable positions. The resulting pressure could help in tablet disintegration [79]. Strain recovery process is unidirectional and exists in the opposite direction of exerted compaction force [78]. The recovery and relaxation of the stressed particles promotes rapid movement and volume expansion, causing the breakage of bonding bonds.

Interruption of particle-particle bonds

Interruption of particle-particle bonds is considered one of the most important mechanisms for tablet disintegration. Some previous studies suggested three different possible bonding mechanisms involved in tabletting which are solid bridges, mechanical interlocking, and intermolecular forces [85]. Among those three bonding mechanisms, intermolecular forces are considered the most prevalent bonding mechanism in tablet disintegration [85, 86]. Various techniques have been introduced to identify the intermolecular bonds involved in the interruption of the tablet matrix. Luangtana-Anan et al. [87] showed a correlation between the intermolecular forces present in tablets and the disintegration time.

Heat of interaction

Two types of interactions result from the interaction of materials with aqueous media: endothermic (heat absorption) and exothermic (heat generation) [77]. Exothermic interactions are obtained from interacting disintegrants with the aqueous media, either water or buffer compartment [88], hence the heat generated causes localized stress within tablets which is usually associated with an expansion of air retained in the tablet compact, and subsequently increased disintegration time. Lowenthal [87] illustrated the importance of heat generation as an important mechanism in tablet disintegration. However, Luangtana-Anan et al. [88] explained the changes in endotherm for different disintegrants and concluded that the amount of heat generated by wetting is rather small and insufficient to cause effective expansion of the entrapped air in the tablet compact. Furthermore, Caramella et al. [89] studied the relation between the temperature of the disintegration media and disintegration time and concluded that increasing the temperature of the aqueous media did not necessarily improve the disintegration process. Therefore, it is necessary to further study the mechanism of heat of interactions to identify its impact on tablet disintegration.

Coprocessed and multifunctional excipients

Developing a robust tablet formulation that can be easily scaled up to a drug product without any problematic issues is a big challenge. Today, there are many challenges in product manufacturing and scaling up; therefore, the need of new pharmaceutical techniques and novel excipients are necessary for manufacturing a high-quality product. Coprocessed and multifunctional excipients are designed to improve the formulation experience and performance. They are high-functionality excipients containing one or more different binders, disintegrants, superdisintegrants and/or lubricants that could provide superior binding, high mechanical strength, quick disintegration and dissolution. The basic principle of coprocessing is based on particle engineering technologies. Any powdered substance is characterized by three different levels of solid-state;
molecular level (individual molecule level), particle level (individual solid particle level) and bulk level (as assembly of particulate species) [90]. These different levels are closely connected to each other in which changing in one level affects the other levels. The molecular level involves the arrangement of individual molecules in the crystal lattice and represented by polymorphism, pseudopolymorphism, and the amorphous state. Particle level involves individual solid particle properties like arrangement, shape, size, surface area, and porosity. The bulk level involves large numbers of particles together and their properties like flowability and compressibility. All these levels are essential for evaluating the performance of excipients.

Methods of coprocessing include spray-drying, granulation, extrusion/spheronization, melt-extrusion, solvent-evaporation and crystallization. Examples of commonly used coprocessed and multifunctional excipients are listed in table 3. Coprocessed and multifunctional excipients represent the ultimate solution in developing orodispersible tablets with very few excipients and high functionalities and physicomechanical properties.

### Table 3: The most common examples of high-functionality excipients

| Excipient | Composition                                                                 | Manufacturer |
|-----------|------------------------------------------------------------------------------|--------------|
| Prosolv® SMCC | Silicified Microcrystalline Cellulose, Microcrystalline Cellulose, Colloidal Silicon Dioxide, Sodium Starch Glycolate, Sodium Stearyl Fumarate | JRS Pharma   |
| Prosolv® EASYtab SP | Microcrystalline Cellulose, Silicon Dioxide, Crosscarmellose Sodium, Magnesium Stearate | JRS Pharma   |
| Prosolv® EASYtab Nutra CM | Microcrystalline Cellulose, Silicon Dioxide, Crosscarmellose Sodium, Magnesium Stearate | JRS Pharma   |
| Prosolv® EASYtab Nutra GM | Microcrystalline Cellulose, Silicon Dioxide, Crosscarmellose Sodium, Magnesium Stearate | JRS Pharma   |
| Prosolv® EASYtab Nutra CP | Microcrystalline Cellulose, Silicon Dioxide, Crosscarmellose Sodium, Magnesium Stearate | JRS Pharma   |
| Prosolv® ODT G2 | Microcrystalline Cellulose, Silicon Dioxide, Mannitol, Fructose, Crosspovidone | JRS Pharma   |
| Mannogem® EZ | Spray-dried Mannitol, Sprayed silicone dioxide | SPI Pharma    |
| Mannogem® XL | Spray-dried Mannitol, Sprayed silicone dioxide | SPI Pharma    |
| Compressol® SM | Mannitol, Sorbitol, Sprayed silicone dioxide | SPI Pharma    |
| Advantose® 100 | Spray-dried Maltose, Sprayed silicone dioxide | SPI Pharma    |
| Advantose® FS95 | Spray-dried Fructose, Sprayed silicone dioxide | SPI Pharma    |
| Lubripharm® SSF | Sodium Stearyl Fumarate, Sprayed silicone dioxide | SPI Pharma    |
| Pharmaburst® C1 | Mannitol, Sorbitol, Crosspovidone | SPI Pharma    |
| Tabulose® | Colloidal silicone dioxide, Colloidal Microcrystalline Cellulose | Roquette Pharma |
| Pearlitol® | Spray-dried Mannitol, Mannitol, Starch | Roquette Pharma |
| Pearlitol® Flash | Spray-dried Mannitol, Mannitol, Starch | Roquette Pharma |
| Starlac® | Starch, Lactose, Crosspovidone | Roquette Pharma |
| Xylisorb® | Xylitol, Lactose, Crosspovidone | Roquette Pharma |
| Ludipress® | Povidone, Crosspovidone, Polyvinyl acetate | BASF Pharma   |
| Ludiflash® | D-mannitol, Crosspovidone, Povidone | BASF Pharma   |
| Soluplus® | Polyethylene glycol, Polyvinyl acetate, Polyvinylcaprolactame | BASF Pharma   |
| Sepitrap™ B0 | Magnesium Aluminometaasilicate, Polysorbate 80 | SEPPIC       |
| Sepitrap™ 4000 | Magnesium Aluminometaasilicate, Polyoxy 140 Hydrogenated Castor Oil | SEPPIC       |
| HiCel™ HFE | Microcrystalline Cellulose, Mannitol, Microcrystalline Cellulose, Guar gum | Sigachi Industries Pvt. Ltd |
| HiCel™ CE15 | Microcrystalline Cellulose, Colloidal Silicone dioxide | Sigachi Industries Pvt. Ltd |
| HiCel™ SMCC | Microcrystalline Cellulose, Mannitol, Microcrystalline Cellulose, Guar gum | Sigachi Industries Pvt. Ltd |
| HiCel™ 80 and 100 | Microcrystalline Cellulose, Lactose Monohydrate, Microcrystalline Cellulose | Sigachi Industries Pvt. Ltd |
| HiCel™ DG | Dicalcium phosphate, Lactose Monohydrate, Microcrystalline Cellulose | Sigachi Industries Pvt. Ltd |
Patented technologies

Several patented technologies are introduced for the manufacture of ODTs [14, 25, 53], including: (1) Zydus* technology [22], (2) Lyoc® technology [92], (3) WowTab® technology [93, 94], (4) FlashTab® technology and Multiflash® [49], (5) Durasolv® and Orasolv® technologies [95, 96], (6) Frosta® technology [14], (7) AdvaTab® technology [97], (8) FlashDose® technology [98], (9) OraQuick® technology [14], (10) Nanocrystal® and EFVDAS® and FastMelt® technologies [14, 99], (11) QuickDis® technology, and (12) Pharmabrust™ technology [14]. Table 4 summarizes the patented techniques used for the manufacture of ODTs and table 5 shows examples of globally marketed oral disintegrating tablets products.

Table 4: Patented technologies used to produce ODTs

| Technology | Company | Description | Novelty aspect | Advantages | Disadvantages |
|------------|---------|-------------|----------------|------------|---------------|
| Zydis® [22] | R. P. Scherer Corporation | Lyophilizing the drug in a water-soluble matrix usually consisting of mannitol (a crystalline sugar) and gelatin (a water-soluble polymer). Other excipients can be used depending on the properties of the drug. | First marketed new tablet technology | Self-preservation, Rapid disintegration and dissolution, Improved bioavailability | Expensive manufacturing process, Require special packaging materials, Unstable at higher temperature and humidity, Incompatible with high drug doses |
| Lyoc® [92] | Cephalon Corporation | A freeze drying process but differ from Zydis where the drug product is frozen on freeze dryer shelves. The homogeneous liquid or suspension is placed into blister cavities and subjected to freeze drying. The homogeneous liquid or suspension contains one or more water-soluble fillers, thickening agents, surfactants and the drug substance. | A modified form of Zydis | Self-preservation | Expensive manufacturing process, Require high amounts of fillers to prevent possible sedimentation, The high amounts of fillers can reduce tablet porosity and prolong disintegration, Incompatible with high drug doses, No significant change in drug bioavailability |
| WowTab® [93, 94] | Yamanouchi Pharma Technologies | - Wow means without water - This process involves granulating low-moldable sugars (e.g. mannitol, lactose, sucrose and glucose) that show rapid dissolution with high-moldable sugars (e.g. sorbitol, maltitol and maltose) with the drug substance. | Combination of low-and high-moldable sugars | Rapid disintegration and dissolution | No significant change in drug bioavailability |
| FlashTab® [49] | Prographar m | This process involves coating a drug with a polymer as Eudragit to provide a rapid drug release in the stomach and formulating this microcapsulated drug with an effervescent base to produce a flash dispersible tablet. This technology comprises the granulation of a drug and excipients by either dry-or wet-granulation then compressed into tablets. | A compressed tablet dosage form containing a drug or microcrystals or microgranules | Conventional tabletting process, Easy to perform, Tablets dissolve within 1 minute. | --- |
| DuraSolv® [95, 96] | Cima Labs, Inc. | - Conventional tabletting process (i.e. a direct compression method using higher compaction pressures during tabletting) | Second generation oral disintegrating tablets | Higher mechanical strength than Orasolv, Good tablet rigidity, Easy to perform, Low cost, Packaged in blisters, foil or bottles | Incompatible with high drug doses because the formulations are subjected to high compaction pressures. Unlike OraSolv, the structural integrity of any taste-masking may be compromised with high drug doses, No significant change in drug bioavailability |
| OraSolv® [95, 96] | Akina Company | - Conventional tabletting process (i.e. direct compression method using an effervescent base and taste masked drug). Effervescence agents cause the tablet to disintegrate rapidly in less than 1 min once contact with water or saliva, leaving coated drug powder. Effervescence agents include carbonates such as sodium bicarbonate, sodium carbonate, potassium bicarbonate and potassium carbonate, magnesium carbonate, and acids like citric, tartaric, fumaric, adipic and succinic. | Unique taste-masking process | Low mechanical strength, Soft and fragile, Tablets; therefore, a special packing material system is required, No significant change in drug bioavailability |
| Frosta® [14] | Akina Company | This technique comprises formulating plastic granules and compressing them at low compaction pressure to produce tablets with high porosity | Formation of highly porous, plastic granules | High mechanical strength, Rapid | --- |

---
| Technology         | Description                                                                                                                                                                                                                     |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| AdvaTab®          | - A microencapsulation process for coating the drug particles with gastro soluble polymer to mask the bitter taste along and prevent the drug dissolution in mouth cavity. It can be combined with Eurand’s complimentary particle technologies as Microcap® (taste-masking technology) and Diffucaps® (controlled release technology). |
| Eurand            |                                                                                                           |
| FlashDose®        | - This technique comprises a unique spinning mechanism to produce a floss-like crystalline structure, much like cotton candy process. This crystalline sugar-based matrix (floss) can incorporate the active drug and be compressed into tablets. Instead of a floss-like crystalline sugar, small spheres of saccharides can be used as a carrier for the drug. |
| Fulsz Technologies, Ltd. |                                                                                                           |
| OraQuick®         | - Taste masking process is done by incorporating drug into matrix microsphere. In this technique, tablets are prepared by dissolving the sugar (e.g. mannitol, sorbitol or sucrose) and protein (gelatin or albumin) in an aqueous, alcoholic or hydroalcoholic solvent. The matrix is then spray dried, yielding highly porous granules. The formed granules are mixed with the drug and other excipients then compressed at low compression force. Unique taste masking process (microencapsulated drug particles) |
| KV Pharmaceutical Co., Inc. |                                                                                                           |
| NanoCrystal       | - The main concept of this technology is decreasing drug particle size and increasing surface area for drug absorption. Nanocrystalline particles are small particles of the drug substance, typically less than 1000 nm in diameter, which are manufactured by milling the drug substance using a suitable wet-milling method. Nanocrystalline colloidal dispersions of drug substances have been combined with water-soluble ingredients as mannitol and sorbitol, filled into blisters, and freeze-dried. The resultant blisters are remarkably robust yet dissolve in very small quantities of water in matter of seconds. This approach is suitable with highly potent or hazardous materials. Wet-milling technique |
| Elan Corporation  |                                                                                                           |
| EFVDAS®           | - Known as Effervescent Drug Absorption System (EFVDAS) Examples of EFVDAS products are acetaminophen, cimetidine, ibuprofen and naproxen. Effervescent Drug Absorption System |
|                   |                                                                                                           |
| Fast Melt®        | - Combine the advantages of liquid formulations with those of solid dosage forms. Characterized by highly porous, micro-fine matrix tablet. Once placed onto the oral cavity, the matrix tablet rapidly absorbs water and disintegrates, and the drug is released into the oral cavity. Highly porous, micro-fine matrix tablet |
| SPI Pharm          |                                                                                                           |
| Pharmabrust™      | - Tablets are manufactured by direct compression of drug substances, pharmabrust, flavours, colorants and a lubricant. Tablets dissolve within 30-40 seconds. Tablets have sufficient strength and can be packed in blister packs and bottles. Direct compression using Pharmabrust as a novel multifunctional excipient |

---

**Int J Pharm Pharm Sci, Vol 11, Issue 9, 8-20**
| Commercial product         | Active ingredient                                    | Indication                                      | Manufacturer                        | Technology |
|----------------------------|------------------------------------------------------|-------------------------------------------------|-------------------------------------|------------|
| Ability®®                  | Aripiprazole                                         | Anti-psychotic                                  | Otsuka America                      | Zydus®     |
| Children's Dimetapp® ND    | Loratadine                                           | Anti-histamin                                    | Wyeth Consumer Healthcare           |            |
| Claritin® RediTabs®        | Loratadine                                           | Anti-histamin                                    | Bayern Schering Corporation         |            |
| Feldene Melt*              | Piroxicam                                            | Anti-inflammatory                               | Pfizer                              |            |
| Grastek® Sublingual Tablets| Pollen allergen extract from Timothy grass (P. pratense) | Timothy grass or related grass-pollen allergies | Calentra Pharma Solutions           |            |
| GrazaX 75,000 SQ-T Oral    | Pollen allergen extract from Timothy grass (P. pratense) | Timothy grass or related grass-pollen allergies | ALK-Abelló A/S                      |            |
| Lyophilisate               |                                                     |                                                |                                     |            |
| Imodium®® Instant          | Loperamide HCl                                      | Anti-diarrheal                                   | Johnson & Johnson                   |            |
| Melts/Imodium® Lingual/    | Clonazepam                                           | Anti-convulsive and Anxiolytic                   | Roche                               |            |
| Imodium®® Quick Dissolve   |                                                     |                                                |                                     |            |
| Klonep®® Wafers            | Risperidone                                          | Anti-psychotic                                  | Johnson & Johnson                   |            |
| Maxalt-MLT®                | Rizatriptan benzoate                                  | Anti-migraine                                    | Merck                               |            |
| Motidium®®                | Domperidone                                          | Anti-emetic                                      | Johnson & Johnson                   |            |
| Onodansetron-RL Zydis® Wafers| Onodansetron HCl                                  | Anti-emetic                                      | GlaxoSmithKline                     |            |
| Ondaz Zydis® Wafers        | Onodansetron HCl                                     | Anti-emetic                                      | Sandoz                              |            |
| Pepecid®®                  | Famotidine                                           | Anti-ulcer                                      | Merck                               |            |
| Ragiwik®® Sublingual Tablets| Pollen allergen extract from Short Ragweed (A. pratense) | Ragweed pollen allergies                        | ALK-Abelló A/S                      |            |
| Risperdal® M-Tab™          | Risperidone                                          | Anti-psychotic                                  | Johnson & Johnson                   |            |
| Zelar®®                    | Selegiline HCl                                       | Parkinson’s disease                             | Elan/Amarin Corporation             |            |
| Zofran® OD                 | Ondansetron HCl                                      | Anti-emetic                                      | GlaxoSmithKline                    |            |
| Zuprin®                    | Tepoxalin                                            | Anti-inflammatory                               | Schering Corp.                      |            |
| Zyprexa®®                  | Olanzapine                                           | Anti-psychotic                                  | Eli Lilly                           |            |
| Loperamide® Lyoc®          | Loperamide chloride                                  | Anti-diarrheal                                   | Teva                                | Lyco®      |
| Paralyoc®®                 | Paracetamol                                          | Analgesic, anti-pyretic                          | Teva                                |            |
| Proxaboc®®                 | Piroxicam                                            | Anti-inflammation                               | Teva                                |            |
| Seglor® Lyoc®              | Dihydroergotamine mesylate                           | Migraine                                        | UCB Pharma                          |            |
| Sermon® Lyoc®              | Nicergoline                                          | Potent vasodilator                              | Pfizer                              |            |
| SpasponLyoc®               | Phloroglucinol dihydrate                             | Anti-spasmodic                                   | Teva                                |            |
| Vogaflene® Lyoc®           | Metopimazine                                         | Anti-emetic                                      | Teva                                |            |
| Reminly® OD Tablets        | Galantamine                                          | Alzheimer’s disease                             | Janssen/Takeda                      | Quicksol®  |
| Risperdal® M-Tab™          | Risperidone                                          | Anti-psychotic                                  | Janssen Pharma                      |            |
| Allegra®®                  | Fexofenadine                                         | Anti-histamin                                    | Aventis Pharmaceuticals             | OraSolv®   |
| Clarinex RediTab®          | Desloratadine                                        | Anti-histamin                                    | Schering-Plough                     |            |
| Fluid®®                   | Famotidine                                           | Anti-ulcer                                      | Azur Pharma                         |            |
| Grapec®® OD                | Prasugrel sodium phosphate                           | Anti-ulcer                                      | Condieon Pharmaceuticals            |            |
| Riemeron® SoTab            | Mirtazapine                                          | Anti-depressant                                  | Organon Inc.                        |            |
| Tempora® Quicklets/        | Acetaminophen                                        | Analgesic                                       | Bristol Myers Squibb                |            |
| Tempra® FirstTabs          |                                                     |                                                |                                     |            |
| Tramirin® Gold Cough       | Chlorpheniramine maleate, Dextromethorphan HBr, Pseudoephedrine HCl | Cold cough                                      | Novartis Consumer Health            |            |
| Softchews®®                |                                                     |                                                |                                     |            |
| Zomig®® Rapinelt           | Zolmitrine                                          | Migraine                                        | AstraZeneca                         |            |
| Alavert®®                  | Loratadine                                           | Anti-histamin                                    | Wyeth Consumer Healthcare           | DuraSolv®  |
| Dimetapp® ND               | Loratadine                                           | Anti-histamin                                    | Wyeth Consumer Healthcare           |            |
| FazaClo®® (low dose) and   | Clozapine                                            | Schizophrenia                                    | Alamo Pharmaceuticals               |            |
| FazaClo®® (high dose)      |                                                     |                                                |                                     |            |
| Kemstro®®                  | Baclofen                                             | Anti-spastic analgesic                           | Schwarz Pharma                      |            |
| Niravam™®                  | Alprazolam                                           | Anxiety                                          | Schwarz Pharma                      |            |
| Nu-Leve®                   | Hydroxyamine sulfate                                 | Antispasmodic                                    | Schwarz Pharma                      |            |
| Benadryl® Fastmelt®        | Diphenhydramine Citrate                              | Anti-histamin                                    | Pfizer                              | WowTab®    |
| Gaster®® D                 | Famotidine                                           | Anti-ulcer                                      | Yamanouchi                          |            |
| Harnal® D                  | Tamsulosin HCl                                      | Benign prostatic hyperplasia                    | Astellas Pharma Inc.               |            |
| Irribow® OD                | Ramosetron HCl                                      | Irritable bowel syndrome                         | Astellas Pharma Inc.               |            |
| Nasea® OD                  | Ramosetron HCl                                      | Anti-emetic                                      | Yamanouchi                          |            |
| Vescicare® OD              | Solfenamcin succinate                               | Overactive bladder                               | Astellas Pharma Inc.               |            |
| Calpol® Six Plus Fastmelts | Paracetamol                                          | Analgesic, anti-pyretic                          | McNeil Products Ltd                 | Flastab®   |
| DolFlash®®                 | Acetaminophen                                        | Analgesic, anti-pyretic                          | Sanofi-Aventis                      |            |
| Excedrin Quicktabs®        | Acetaminophen, Caffeine                              | Analgesic, anti-pyretic                          | Bristol Myers Squibb                |            |
| Nurofen® Flashtab®         | Ibuprofen                                           | Analgesic, anti-pyretic                          | Boots Healthcare                    |            |
| Ondansetron Flashtab®      | Ondansetron                                          | Anti-emetic                                      | Teva                                |            |
| OxynormOro®®               | Oxycodone chloride hydrate                            | Cancer related pain                              | Mundipharma                         |            |
| Paracetamol Flashtab®      | Paracetamol                                          | Analgesic, anti-pyretic                          | Ranbaxy                             |            |
Characterizations of oral disintegrating tablets

Evaluation of powders or granules (pre-compression parameters evaluation)

Bulk and tapped density

Ten gm of a dry powder or granular sample is placed in a 100 ml graduated cylinder. The volume occupied by the powder or granules is measured and the bulk density is calculated using equation 3.

\[
 \text{Bulk density} = \frac{\text{Weight of the powder}}{\text{Bulk volume of the powder}} \quad (\text{Eq. 3})
\]

Tapped density is determined by a tapped density tester. The volume occupied by the powder or granules after tapping is used to calculate the tapped density using equation 4 [40, 100].

\[
 \text{Tapped density} = \frac{\text{Weight of the bulk sample}}{\text{Bulk volume of the sample on tapping}} \quad (\text{Eq. 4})
\]

Hausner ratio and carr's compressibility index

Hausner ratio and carr's compressibility index are calculated based on bulk and tapped density results using equations 5 and 6, respectively.

\[
 \text{Hausner ratio} = \frac{\text{Tapped density}}{\text{Bulk density}} \quad (\text{Eq. 5})
\]

\[
 \text{Carr's compressibility index} = \left( \frac{\text{Tapped density}}{\text{Bulk density}} \right)^{100} \quad (\text{Eq. 6})
\]

Flowability is determined based on the results of hausner ratio and carr's compressibility index as shown in table 6.

Table 6: Specification for hausner ratio and carr's compressibility index

| Hausner ratio | Carr’s compressibility index (%) | Flowability |
|---------------|---------------------------------|-------------|
| 1.00-1.11     | 0-10                            | Excellent   |
| 1.12-1.18     | 11-15                           | Good        |
| 1.19-1.25     | 16-20                           | Fair        |
| 1.26-1.34     | 21-25                           | Passable    |
| 1.35-1.45     | 26-31                           | Poor        |
| 1.46-1.59     | 32-37                           | Very poor   |
| >1.60         | >38                             | Very, very poor |

Angle of repose (θ)

Angle of repose (θ) is determined by the fixed funnel and free-standing cone method. The method employed a funnel that is fixed at a certain height (h) on a graph paper placed on a flat horizontal surface. The powder or granules sample is carefully passed through the funnel till the apex at the conical pile touched the tip of the funnel. Thus, with \( r \) being the radius of the base of the conical pile as shown in equation 7 [101].

\[
 \tan \theta = \frac{h}{r} \quad (\text{Eq. 7})
\]

Flowability is determined based on the results of angle of repose as shown in table 7.

Table 7: Specification of angle of repose (θ)

| Angle of repose (degree) | Flowability |
|--------------------------|-------------|
| 25–30                    | Excellent   |
| 31-35                    | Good        |
| 36-40                    | Fair        |
| 40-45                    | Passable    |
| 46-55                    | Poor        |
| 56-65                    | Very poor   |
| >66                      | Excellent   |

Porosity (ε)

Porosity (ε) is calculated from apparent density (ρ_{app}) and true density (ρ_{true}) as in equation 8 [40].

\[
 \varepsilon = \left[ 1 - \left( \frac{\rho_{app}}{\rho_{true}} \right) \right] \times 100 \quad (\text{Eq. 8})
\]

The true density (ρ_{true}), which is the density of the particles that make up a powder or particulate solid, is measured by gas displacement using a pycnometer [102].
Evaluation of tablets (post-compression parameters evaluation)

(1) Weight uniformity or % of weight variation

Twenty tablets were randomly selected from the production batch and weighted individually to check their weight uniformity. The average tablet weight (mg) was lost [40, 103]. Tablets pass the friability test if not more than 1% of the tablets collected and reweighted. The percentage of weight loss in tablet is calculated using equation 10 and taken as a measure of friability. Tablets pass the friability test if not more than 1% of the tablets weight was lost [40, 103].

Table 8: Uniformity of weight of tablets

| Average tablet weight (mg) | % Deviation |
|----------------------------|-------------|
| Less than 80 mg            | ±10         |
| More than 80 mg but less than 250 mg | ±7.5        |
| 250 mg and more            | ±5          |

**Tablet hardness**

Tablet hardness is measured by the hardness tester in newton (N) or kilopond (kP) per unit tablet. Each tablet is placed individually in the hardness tester and the crushing load is measured. In general, the hardness of ODTs is set to be lower than conventional tablets because of increasing hardness results in decreasing tablet disintegration rate [40, 103].

**Tablet friability**

Twenty tablets are accurately weighted and placed in the friabulator chamber, then allowed to rotate at 25 rpm for 4 min. Tablets are collected and reweighted. The percentage of weight loss in tablet is calculated using equation 10 and taken as a measure of friability. Tablets pass the friability test if not more than 1% of the tablets weight was lost [40, 103].

\[
\% \text{Friability} = \left( \frac{W_f - W_i}{W_i} \right) \times 100 \quad \text{(Eq. 10)}
\]

\( W_i \) = initial weight of tablets
\( W_f \) = final weight of tablets

**Tablet thickness and diameter**

Tablet thickness and diameter are measured by using a micrometer caliper in millimeter (mm) per unit tablet [40].

**Uniformity of dispersion**

Twenty tablets are placed in a beaker containing 100 ml of purified water and stirred gently for 2 min. The dispersion is allowed to pass through 22 mesh screen. Tablets would pass the test if no residue remained on the screen [104].

**Water absorption ratio**

A small piece of tissue paper folded twice is placed in a small petridish containing 6 ml of purified water. A tablet is placed onto the tissue paper and the time required for completely wetted is measured. The wetted tablet is then re-weighed. Water absorption ratio (R) is calculated by using equation 11 [104].

\[
R = \left( \frac{W_t - W_b}{W_b} \right) \times 100 \quad \text{(Eq. 11)}
\]

\( W_t \) = the weight of tablet before water absorption
\( W_b \) = the weight of tablet after water absorption

**Wetting time**

Five circular tissue papers of 10 cm diameter are placed in a petridish with a 10 cm diameter. Ten millimeters of water containing Eosin, a water-soluble dye, is added to petridish. A tablet is carefully placed on the surface of the tissue paper. The time required for water to reach upper surface of the tablet is noted as a wetting time [50, 101].

**In-vitro disintegration time**

Disintegration time is evaluated using the disintegration tester without disk. The disintegration medium is usually 900 ml of purified water kept at 37 ±0.5 °C. The time required for complete disintegration is in seconds [40, 103].

**In-vitro and comparative dissolution**

Four dissolution medias are commonly used for evaluating in vitro and comparative dissolution, namely 0.1N HCl (pH 1.2), acetate buffer (pH 4.5), phosphate buffer (pH 6.8) and artificial saliva (pH 7.0). Dissolution tester is used for experimental evaluation following the USP paddle (most common). All dissolution tests are usually conducted in 900 ml of each dissolution media maintained at a constant temperature of 37 ±0.5 °C with paddle rotation speed of 25, 50, 75 or 100 rpm. Comparative dissolution studies is mainly conducted against the reference marketed product. Dissolution profiles are compared with the reference marketed product using the similarity factor (f2) defined by the following equation 12 [40, 103].

\[
t_2 = 50 \left( \frac{1}{n} \sum (R_i - T_i)^2 \right)^{0.5} \quad \text{(Eq. 12)}
\]

Where \( n \) is the number of sampling time points, \( R_i \) and \( T_i \) are the mean percent dissolved of the reference product and the prepared ODTs respectively, up to each time point \( t \), \( f_2 \) represents a logarithmic transformation of the sum-squared error of difference between the reference and the test products over all time points. In order to consider similar dissolution profiles, \( f_2 \) values should be higher than 50.

**Novel formulations of oral disintegrating tablets**

Many reported applications of ODTs have been described in the literature. Agiba et al. [40] incorporated a high dose of nutraceuticals glucosamine sulphate (GluS) and chondroitin sulphate (CS) into ODTs in order to improve their disintegration, dissolution and subsequent their bioavailability. GluS/CS ODTs were prepared by direct compression and melt-granulation techniques, using a blend of conventional and coprocessed multifunctional excipients as Pharmaburst™ C1. Pharmaburst™ C1 turned out to be the key excipient in improving the tablet characteristics, disintegration and dissolution profile. Kumar and Saharan [101] developed ODTs of salbutamol sulphate, using a combination of three different superdisintegrants in different ratios. They concluded that the binary combination of superdisintegrants was more effective in disintegration and dissolution than the individual use of one superdisintegrant. Dave et al. [105] developed ODTs of chlorpheniramine maleate based on lyophilization technique, using superdisintegrants as croscarmellose sodium and crospovidone for faster disintegration and dissolution. Tükan et al. [106] developed fesofenadine hydrochloride ODTs by direct compression using high functionality excipients as F-Melt®, Pearlitol® Flash, Pharmaburst® 500, Prosolv® Easytab SP, Ludiflash® and Parteck® OD. ODTs formulated with Pharmaburst® 500 were the most promising formulation with respect to physical characteristics and dissolution rate. Shoormeij et al. [107] developed meloxicam ODTs using solid dispersions followed by direct compression. Meloxicam solid dispersions were prepared by the melting method, using poloxamer 188 as a hydrophilic carrier and crospovidone as a superdisintegrant. Moqbel et al. [108] developed ODTs of...
chlorozoxazone using two different approaches; co-processed excipients or liquid solid technique. F-melt®, Pearlitol® flash, Pharmapur® 500, Prosoolv® ODT and Starlac® were used as co-processed multifunctional excipients, whereas in liquid solid method, Avicel® PH101, Celluclast® 80 and Microcel® 100 were used as carriers, while Aerosil® 200 was a coating material. Both approaches were capable of producing ODTs with ease and low cost of manufacture. ODTs formulated with Pharmapur® 500 showed the best results in terms of palatability, mechanical strength, disintegration and dissolution. Ibrahim and El Sayeh [109] formulated orally disintegrating tablets containing furosemide, a potent diuretic used mainly in the management of hypertension. ODTs were prepared by direct compression method for taste-masking purposes. Nishiyama et al. [110] prepared taste-masking granules of lafutidine for ODTs using water-insoluble/water-soluble polymers combinations. Lafutidine taste-masking granules were prepared by coating lafutidine granules with a taste-masking layer prepared by combining ethylcellulose (water-insoluble polymer) and hypromellose (water-soluble polymer), and ODTs were prepared by direct compression method using mannitol as a diluent, low-substituted hydroxypropyl cellulose as a disintegrant and sodium stearyl fumarate as a water-soluble lubricant. Desai et al. [111] developed β-cyclodextrin (β-CD) solid dispersion-based ODTs of eslicarbazepine acetate (ESL), for improving the dissolution and providing rapid anti-epileptic action. ESL-β-CD solid dispersion was prepared by solvent evaporation method and then compressed into ODTs by direct compression, using superdisintegrants as crosspovidone, sodium starch glycolate, pregelatinized starch and croscarmellose. Microcrystalline cellulose was further added to aid in tabletting. Yildiz et al. [112] developed new ODTs containing mirtazapine; an antidepressant drug molecule having bitter taste by coacervation followed by direct compression using different fillers (Ludiflash®, Pharmapur® Cl, Galen® IQ, F-Melt® and Mannitol Poretek® M100), disintegrants (Kollidon® CL, Ac-Di-Sol®, Esplotal® and Kollidon® CL/Ambertix® IR-88 mixture), glidant (Aerosil® 200), citric acid and sodium carbonate (effervescent mixture). Chen et al. [113] prepared montelukast sodium ODTs with a similar dissolution profile as the marketed product, Romilast® ODTs (Ranbaxy). Montelukast sodium ODTs were prepared by direct compression and wet-granulation methods, using a variety of excipients such as microcrystalline cellulose (M105 and M301), mannitol (SD200 and 160C), croscarmellose sodium, hydroxypropyl cellulose, and magnesium stearate. The prepared ODTs showed equivalent dissolution profiles to the marketed product in four different media, El-Maghraby and El-Sergany [114] enhanced the intra-oral absorption of losartan potassium used in the treatment of angina pectoris and hypertension by its formulation in ODTs with subsequent fast dissolution. Nisoldipine ODTs were formulated by solid dispersion technique by using solvent evaporation method. Cantor et al. [115] described a novel formulation approach for taste-masking drugs with poor organoleptic properties such as clindamycin in hydrochloride. Taste-masked ODTs of clindamycin hydrochloride were prepared by its coating with microcrystalline cellulose beads followed by the addition of a taste-masking layer of amino methacrylate copolymer coating suspension.

Future prospects and possible challenges in the development of oral disintegrating tablets

Despite the advances in ODT technologies, formulation of hydrophobic drugs with poor bioavailability is still a big challenge, particularly at high doses. The need of a new technology to incorporate higher doses of hydrophobic drugs without affecting the mechanical and disintegrating properties is crucial. The disintegration times of most marketed ODTs are acceptable (within 3 min as stated by European Pharmacopeia), but certainly further improvement would be an advantage. Generally, the disintegration time is affected by many formulation variables, therefore, a balance between the disintegration time and other tablet properties as mechanical strength, friability, thickness and diameter should be well considered. Development of cheap and effective direct taste-masking methods would also be advantageous. On the other hand, the development of ODTs usually requires large amounts of excipients and having large drug doses will make the final dosage form very large. Therefore, the formulation of ODTs containing high doses drugs is still a problematic issue and need further new and advanced technologies.

CONCLUSION

The popularity of ODTs has increased dramatically over the last few decades. There are many globally marketed products that have been formulated into ODT dosage forms. The most important parameters in ODT formulations are rapid onset of action, very fast drug release, quick disintegration and dissolution, and these could be achieved by formulating tablets with high porous structures or by adding a blend of disintegrants, superdisintegrants, effervescent systems, and/or co-processed multifunctional excipients. ODTs prepared by direct compression technique usually have good mechanical properties but could be further improved by using high functionality excipients. Considering many advantages and benefits of ODT systems, it is only a matter of time till the majority of oral solid dosage forms become ODT formulations.

ACKNOWLEDGEMENT

The authors would like to thank Dr Sherif Lashin, R&D Director, Dr Abla Abdel Aziz, R&D Senior Manager, SIGMA Pharmaceutical Industries; Dr Wageeh Abdel Hakeem, R&D Deputy Manager, October Pharma; Dr Maha Nasr, Associate Professor of Pharmaceutics and Industrial Pharmacy, Ain Shams University in Cairo and Mutah University in Jordan; and Dr Hanan Refai, Professor of Pharmaceutics and Industrial Pharmacy, Cairo University and Missr University for Science and Technology in Egypt for their fruitful discussions on the theme of the review article.

AUTHORS CONTRIBUTIONS

All the authors have contributed equally.

CONFLICT OF INTERESTS

The authors report no conflicts of interest.

REFERENCES

1. Pather SI, Rathbone MJ, Senel S. Oral transmucosal drug delivery. Drug Pharm Sci 2008;183:53.
2. Rathbone MJ, Drummond BK, Tucker IG. The oral cavity as a site for systemic drug delivery. Adv Drug Delivery Rev 1994;13:1-22.
3. Rathbone MJ, Senel S, Pather I. Oral mucosal drug delivery and therapy. Springer 2015. Doi:10.1007/978-1-4987-7558-4.
4. Squire CA, Wertz PW. Structure and function of the oral mucosa and implications for drug delivery. Drugs Pharm Sci 1996;74:1-26.
5. Senel S, Hinal AA. Drug permeation enhancement via buccal route: possibilities and limitations. J Controlled Release 2001;72:133-44.
6. Collins L, Dawes C. The surface area of the adult human mouth and thickness of the salivary film covering the teeth and oral mucosa. J Dent Res 1987;6:1300-2.
7. Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery. Clin Pharmacokinet 2002;41:661-80.
8. Avery Smith W, Dellarosa DM. Approaches to treating dysphagia in patients with brain injury. Am J Occup Ther 1994;48:235-9.
9. Sastry SV, Nisshadham JR, Fik JA. Recent technological advances in oral drug delivery—a review. Pharm Sci Tech Today 2000;3:138-45.
10. Porter SC. Novel drug delivery: review of recent trends with oral solid dosage forms. Am Pharm Rev 2001;4:28-36.
11. Bhandari S, Mittapalli RK, Gannu R, Rao YM. Orodispersible tablets: an overview. Asian J Pharm 2008;2:2-11.
12. Wilson C, Washington N, Peach J, Murray G, Kemery J. The behaviour of a fast-dissolving dosage form (Expidet) followed by y-scintigraphy. Int J Pharm 1987;40:119-23.
13. Brown D. Orally disintegrating tablets-taste over speed. Drug Delivery Technol 2003;3:58-61.
14. Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug Carrier Sys 2004;21:433-76.
15. Braddock R, Shahani S, Poojary S, Deewan B, Sudarshan S. Fast dissolving drug delivery systems. Jama India 2001;4:27-31.
26. Ghosh T, Ghosh A, Prasad D. A review on new generation orodispersible tablets and its future prospective. Int J Pharm Sci 2011;3:1-7.

27. Dobetti L. Fast-melting tablets: developments and technologies. Pharm Tech 2001;12:44.

28. Reddy L, Ghosh B. Fast dissolving drug delivery systems: a review of the literature. Indian J Pharm Sci 2002;64:331.

29. Aurora J, Pathak V. Oral disintegrating technologies: Oral disintegrating dosage forms: an overview. Drug Delivery Technol 2005;5:50-4.

30. Sugihara M, Hidaka M, Saito A. Discriminatory features of dosage form and package. Japan Hosp Pharm 1986;12:322-8.

31. Habib W, Khankari R, Hontz J. Fast-dissolve drug delivery systems. Crit Rev Ther Drug Carrier Syst 2000;17:61-72.

32. Seager H. Drug-delivery products and the Zydus fast-dissolving dosage form. J Pharm Pharmaeol 1998;50:375-82.

33. Iles MC, Atherton AD, Coppin NM. Freeze-dried dosage forms and methods for preparing the same. US Patent 518825A; 1993.

34. O’Connor RE, Schwartz JB. Extusion and spheronzation technology. Pharm Pelletization Tech 1989;37:116-20.

35. Agarwal V, Kothari B, Moe D, Khankari R. Drug delivery: fast-dissolve systems. Encyclopedia Pharm Tech 2006;2:1104-14.

36. Fini A, Bergamante V, Gescel GC, Ronchi C, de Moraes CAE. Fast dispersible/slow releasing ibuprofen tablets. Eur J Pharm 2008;69:335-41.

37. Masters K. Part I-basie principles, definitions—§ 1 spray drying fundamentals: process stages. Spray Drying Handbook. 5th edition. Longman Scientific and Technical and John Wiley and Sons, Inc; 1991. p. 32-3.

38. Prasad N, Straus D, Reichart G. CycloDEXtrin flavor delivery systems. US Patent 6287938B1; 2001.

39. Venkatesh D. Formulation of taste masked oro-dispersable tablets of ambroxol hydrochloride. Diss 2005.

40. Hughes L. Selecting the right ion exchange resin. Pharma Quality 2005;1:54-6.

41. Jeong SH, Park K. Development of sustained release fast-disintegrating tablets using various polymer-coated ion-exchange resin complexes. Int J Pharm 2008;353:195-204.

42. Lachman L, Lieberman HA, Kanig JL. The theory and practice of industrial pharmacy. Lea and Febiger Philadelphia; 1976.

43. Bangale GS, Shinde G, Rathinara BS. New generation of orodispersible tablets: recent advances and future prospects. Int J Adv Pharm Sci 2011;2:52-62.

44. Nail SL, Gathin LA. Freeze-drying principles and practice. In: Pharmaceutical Dosage Forms-Parenteral Medications, CRC Press; 2016. p. 366-94.

45. Chaudhari SP, Kotian NR, Bhagdale MM, Bafna VC. Formulation development and evaluation of orally disintegrating tablets of doxazosin mesylate. Asian J Pharm 2012;26:64-70.

46. Wagh VD, Gadlinge V. Taste masking methods and techniques in oral pharmaceuticals: current perspectives. J Pharm 2009;77:327-42.

47. Cousin G, Bruna E, Gendrot E. Rapidly disintegratable multiparticulate tablet. US Patent 5164632A; 1995.

48. Bly S, Sunada H, Yonezawa Y, Danjo K, Otuska A, Iida K. Preparation and evaluation of a compressed tablet rapidly dissolving in the oral cavity. Pharm Res 1996;14:2121-7.

49. Gills PMV, De Conde VVF. Fast-dissolving galanthamine hydrobromide tablet. US Patent 6099863A; 2000.

50. Gattani S, Shiyan B, Kalkade K, Patil A, Surana S. Formulation and production of mouth dissolving tablet of doxazosin hydrochloride by using superdisintegrants. Indian Drugs 2009;46:44-50.

51. Wagh MA, Kothawade DP, Salunkhe KS, Chavan NV, Daga VR. Int J Drug Delivery 2010;2.

52. Heinemann H, Rothe W. Preparation of porus tablets. US Patent 3885026; 1975.

53. Roser BJ, Blair J. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof. US Patent 5762961; 1998.

54. Lo JB. Method of producing porus delivery devices. WO Patent 9318757; 1993.

55. Rowe VC, Sheskey PJ, Owen SC. Handbook of pharmaceutical excipients. Pharmaceutical Press London; 2009. p. 9.

56. Shangraw R, Wallace JW, Bowers F. Morphology and functionality in tablet excipients for direct compression. Pharm Technol 1987;11:136-43.

57. Mattsson S, Nyström C. Evaluation of critical binder properties and development of mouth dissolving tablets by using intragranular disintegrants. Drug Dev Indian Pharm 1992;18:125-39.

58. Kottke M, Chueh HR, Rhodes C. Comparison of disintegrant and binder activity of three corn starch products. Drug Dev Ind Pharm 1992;18:2207-23.

59. Small L, Augsburger L. Aspects of the lubrication requirements for an automatic capsule filling machine. Drug Dev Ind Pharm 1978;4:345-72.

60. Mattsson S, Nyström C. Evaluation of critical binder properties affecting the compressibility of binary mixtures Drug Dev Ind Pharm 2001;27:181-94.

61. Rudnic E, Rhodes C, Welch S, Bernardo P. Evaluations of the mechanism of disintegrant action. Drug Dev Ind Pharm 1982;8:87-109.

62. Khan R, Rhodes C. Water sorption properties of tablet disintegrants. J Pharm Sci 1975;6:447-51.

63. Wall LJ, Prasad KP. Uptake of water by excipients in tablets. Int J Pharm 1989;50:147-53.

64. Thibert R, Hancock BC. Direct visualization of superdisintegrant hydration using environmental scanning electron microscopy. J Pharm Sci 1996;85:1255-8.

65. Gordon MS, Chowhan ZT. Effect of tablet solubility and hygroscopicity on disintegrant efficiency in direct compression tablets in terms of dissolution. J Pharm Sci 1987;76:907-9.

66. Gebre Mariam T, Winneufiller M, Schmidt PC. An evaluation of the disintegration efficiency of a sodium starch glycolate prepared from enset starch in compressed tablets. Eur J Pharm Pharm 1996;42:124-32.

Compressed tablets using mannitol with camphor, a subliming material. Int J Pharm 1997;152:127-31.
70. Gordon MS, Rudraraju VS, Dani K, Chowhan ZT. Effect of the mode of super disintegrant incorporation on disintegration in wet granulated tablets. J Pharm Sci 1993;82:220-6.
71. Khattab I, Menon A, Sakr A. Effect of mode of incorporation of disintegrants on the characteristics of fluid-bed wet-granulated tablets. J Pharm Pharmacol 1993;45:687-91.
72. Kleinebudde P. Application of low substituted hydroxypropylcellulose [HPC] in the production of pellets using extrusion/spherization. Int J Pharm 1993;96:119-28.
73. Schiermeier S, Schmidt PC. Fast dispersible ibuprofen tablets. Eur J Pharm Sci 2002;12:5:295-305.
74. Palmieri A. Polacrill potassium. Handbook of Pharmaceutical Excipients; 2012:7:571-2.
75. Bele MH, Derle DV. Mechanism of disintegrant action of polacrill potassium: Swelling or wicking? Acta Pharm Sinica B 2012;2:70-6.
76. Quodbach J, Kleinebudde P. Systematic classification of tablet disintegrants by water uptake and force development kinetics. J Pharm Pharmacol 2014;66:429-38.
77. Desai PM, Liew CV, Heng PWS. Review of disintegrants and the disintegration phenomena. J Pharm Sci 2016;105:2545-55.
78. Quodbach J, Moussavi A, Tammer R, Frahm J, Kleinebudde P. Tablet disintegration studied by high-resolution real-time magnetic resonance imaging. J Pharm Pharmacol 2014;103:249-55.
79. Moreton RC. Disintegrants in tableting. In: Pharmaceutical Dosage Forms-Tablets, CRC Press; 2008. p. 233-66.
80. Colombo P, Conte U, Caramella C, Geddo M, La Manna A. Disintegrating force as a new formulating parameter. J Pharm Pharm Sci 2014;17:701-5.
81. De Schoenmaker B, Van der Schueren L, De Vrieze S, Westbroek J, De Vetten S. Nanofibrous structures with an optimized method. J Appl Polym Sci 2011;120:305-10.
82. Kissa E. Wetting and wicking. Text Res J 1996;66:660-8.
83. Bolhuis G, Lerk C, Lie-A-Huen L. The role of water uptake on tablet disintegration. Design of an improved method for penetration measurements. Pharm Acta Helv 1986;61:22-9.
84. Patel S, Kaushal AM, Bansal AK. Effect of particle size and compression force on compaction behavior and derived mathematical parameters of compressibility. Pharm Res 2007;24:111-24.
85. Karehill P, Nyström C. Studies on direct compression of tablets XXI. Investigation of bonding mechanisms of some directly compressed materials by strength characterization in media with different dielectric constants (relative permittivity). Int J Pharm 1990;61:251-60.
86. Ferrari F, Bertoni M, Bonferroni M, Rossi S, Caramella C, Nyström C. Investigation on bonding and disintegration properties of pharmaceutical materials. Int J Pharm 1996;136:71-9.
87. Kuangtana Anan M, Catellani P, Colombo P, Dinavandan R, Fell J, Santi P. The role of bond weakening by liquids in the disintegration of tablets. Eur J Pharm Biopharm 1992;38:169-71.
88. Lowenthal W. Mechanism of action of tablet disintegrants. Pharm Acta Helv 1973;48:589-609.
89. Caramella C, Ferrari F, Conte U, Gazzaniga A, La Manna A, Colombo P. Experimental evidence of disintegration mechanisms. Acta Pharm Technol 1989;35:30-3.
90. Kanojia N, Kaur L, Nagpal M, Bala R. Modified excipients in novel drug delivery: need of the day. J Pharm Tech Res Mag 2014;1:81-107.
91. Desai U, Chavan R, Mhatre P, Ginhelic R. A review: e coprocessed excipients. Int J Pharm Sci Res Rev 2012;12:93-105.
92. Lafon L. Galenic form for oral administration and its method of preparation by lyophilization of an oil-in-water emulsion. Patent EP0159237A1; 1986.
93. Mizumoto T, Masuda Y, Kajiyama A, Yanagisawa M, Nishadham JR. Tablets quickly disintegrating in the oral cavity and process for producing the same. US Patent 6589554B1; 2003.
94. Mizumoto T, Masuda Y, Fukui M. Intrabuccally dissolving compressed moldings and production process thereof. US Patent 5576014A; 1996.
95. Wehling F, Schuehle S. Base coated acid particles and effervescent formulation incorporating same. US Patents 5508464A; 1996.
96. Wehling F, Schuehle S, Madamala N. Effervescent dosage form with microcrystals. US Patent 5178878A; 1993.
97. Ohta M, Hayakawa E, Ito K, Tokuno S, Morimoto K, Watanabe Y. Intrabuccally rapidly disintegrating tablet. US Patent 20010014340A1; 2001.
98. Myers GL, Battist GE, Fuhr RC. Process and apparatus for making rapidly dissolving dosage units and product therefrom. US Patent 5851553A; 1999.
99. Kaushik D, Dureja H, Saini T. Orally disintegrating tablets: An overview of melt-in mouth tablet technologies and techniques. Tablets Capsules 2004;2:30-6.
100. US Pharmacopeia. Bulk Density and Tapped Density of Powders; 2015. p. 616.
101. Kumar A, Saharan VA. A comparative study of different proportions of superdisintegrants: formulation and evaluation of orally disintegrating tablets of salbutamol sulphate. Turk J Pharm Sci 2011;7:4-10.
102. Nordström J, Persson A, Lazarova L, Frening G, Alderborn G. The degree of compression of spherical granular solids controls the evolution of microstructure and bond probability during compaction. Int J Pharm 2013;442:3-12.
103. European pharmacopoeia, Strasbourg, France. The directorate for the quality of medicines of the council of Europe 9EDQM; 2002.
104. Arora P, Sethi VA. Orosoluble tablets: a comprehensive review. Int J Res Dev Pharm Life Sci 2013;2:270-84.
105. Dave V, Yadav RB, Ahuja R, Yadav S. Formulation and optimization of novel fast dissolving tablet of chlorpheniramine maleate by using lyophilization techniques. Bull Faculty Pharmacy Cairo University 2017;55:31-9.
106. Türkmen O, Şenyigit ZA, Baloglu F. Formulation and evaluation of fexofenadine hydrochloride orally disintegrating tablets for pediatric use. J Drug Deliv Sci Tech 2017;8:201-10.
107. Shaoraniej Z, Täberi, A, Homayouni A. Preparation and physicochemical characterization of meloxicam orally fast disintegration tablet using its solid dispersion. Braz J Pharm Sci 2017;53. Doi.org/10.1590/s2175-9790201700400176.
108. Mogbel HA, El Meshad AN, El Naharawi MA. Comparative study of different approaches for preparation of chlorozuxone orodispersible tablets. Drug Dev Ind Pharm 2017;43:742-50.
109. Ibrahim MA, Amal El Sayeh F. Optimized furosemide taste masked orally disintegrating tablets. Saudi J Pharm J 2017;25:1055-62.
110. Nishiyama T, Ogata T, Ozeki T. Preparation of bitter taste-masking granules of lafutidine for orally disintegrating tablets using water-insoluble/soluble polymer combinations. J Drug Deliv Sci Tech 2016;3:32-38.
111. Desai S, Doddar A, Sawant K. Formulation of cyclohexirin inclusion complex-based orally disintegrating tablet of eslicarbazepine acetate for improved oral bioavailability. Mater Sci Eng 2016;C:826-34.
112. Yildiz S, Aytekin E, Yavuz B, Bozdag Pehlivan S, Unlu N. Formulation studies for mirtazapine orally disintegrating tablets. Drug Dev Ind Pharm 2016;42:1008-17.
113. Chen Y, Feng T, Li Y, Du B, Weng W. Formulation and evaluation of a montelukast sodium orally disintegrating tablet with a similar dissolution profile as the marketed product. Pharm Dev Tech 2017;22:168-72.
114. El Maghraby GM, Elsergany RN. Fast disintegrating tablets of nisoldipine for intra-oral administration. Pharm Dev Tech 2014;19:641-50.
115. Cantor SL, Khan MA, Gupta A. Development and optimization of taste-masked orally disintegrating tablets (ODTs) of cimadrinyc hydrochloride. Drug Dev Ind Pharm 2015;41:1156-64.